MA55799A - Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2 - Google Patents

Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2

Info

Publication number
MA55799A
MA55799A MA055799A MA55799A MA55799A MA 55799 A MA55799 A MA 55799A MA 055799 A MA055799 A MA 055799A MA 55799 A MA55799 A MA 55799A MA 55799 A MA55799 A MA 55799A
Authority
MA
Morocco
Prior art keywords
aprmilast
combination therapies
therapies including
tyk2 inhibitors
tyk2
Prior art date
Application number
MA055799A
Other languages
English (en)
French (fr)
Inventor
Mary Adams
Lisa Beebe
Gilles Buchwalter
Tiffany Carr
Robert Plenge
Peter Henry Schafer
Te-Chen Tzeng
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MA55799A publication Critical patent/MA55799A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA055799A 2019-04-30 2020-04-30 Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2 MA55799A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/029772 WO2020222773A1 (en) 2019-04-30 2019-04-30 Combination therapies comprising apremilast and tyk2 inhibitors

Publications (1)

Publication Number Publication Date
MA55799A true MA55799A (fr) 2022-03-09

Family

ID=66476870

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055799A MA55799A (fr) 2019-04-30 2020-04-30 Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2

Country Status (14)

Country Link
EP (2) EP3962475A1 (es)
JP (2) JP2022537877A (es)
KR (2) KR20220002488A (es)
CN (2) CN114269336A (es)
AU (2) AU2019443366A1 (es)
BR (2) BR112021021809A2 (es)
CA (2) CA3138473A1 (es)
CL (1) CL2021002847A1 (es)
CO (2) CO2021015614A2 (es)
IL (2) IL287665A (es)
MA (1) MA55799A (es)
MX (2) MX2021013317A (es)
SG (2) SG11202112043PA (es)
WO (2) WO2020222773A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021013317A (es) 2019-04-30 2022-01-18 Celgene Corp Terapias de combinacion que comprenden inhibidores de apremilast y tyk2.
KR20230159421A (ko) 2021-02-19 2023-11-21 수도 바이오사이언시즈 리미티드 Tyk2 억제제 및 이의 용도
AU2022350509A1 (en) * 2021-09-23 2024-04-04 Bristol-Myers Squibb Company Methods of treating hair-loss disorders with tyk2 inhibitors
WO2023076161A1 (en) 2021-10-25 2023-05-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
US8367689B2 (en) * 2009-05-06 2013-02-05 Portola Pharmaceuticals, Inc. Inhibitors of JAK
EP2638018A1 (en) 2010-11-09 2013-09-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors
EP2701701B1 (en) * 2011-04-28 2018-01-24 Celgene Corporation Methods and compositions using pde4 inhibitors for the treatment and management of autoimmune and inflammatory diseases
CN104136003A (zh) * 2011-12-27 2014-11-05 细胞基因公司 (+)-2-[1-(3-乙氧基-4-甲氧基-苯基)-2-甲磺酰基-乙基]-4-乙酰氨基异二氢吲哚-1,3-二酮的制剂
KR20140108594A (ko) 2012-01-10 2014-09-11 에프. 호프만-라 로슈 아게 피리다진 아미드 화합물 및 syk 저해제로서의 이의 용도
US9187453B2 (en) 2012-03-28 2015-11-17 Takeda Pharmaceutical Company Limited Heterocyclic compound
AU2013265307B2 (en) 2012-05-24 2016-04-07 Cellzome Limited Heterocyclyl pyrimidine analogues as TYK2 inhibitors
KR102195194B1 (ko) * 2012-11-08 2020-12-24 브리스톨-마이어스 스큅 컴퍼니 ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 아미드-치환된 헤테로시클릭 화합물
EP2917186B1 (en) 2012-11-08 2017-10-18 Bristol-Myers Squibb Company Alkyl amide-substituted pyrimidine compounds useful in the modulation of il-12, il-23 and/or ifn
AU2014235273A1 (en) * 2013-03-14 2015-07-09 Celgene Corporation Treatment of psoriatic arthritis using apremilast
JPWO2015016206A1 (ja) 2013-07-30 2017-03-02 武田薬品工業株式会社 複素環化合物
SG11201601503SA (en) 2013-09-03 2016-03-30 Sareum Ltd Pharmaceutical compounds
TWI582077B (zh) 2013-11-07 2017-05-11 必治妥美雅史谷比公司 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
ES2702126T3 (es) 2013-12-10 2019-02-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
WO2015091584A1 (en) 2013-12-18 2015-06-25 F. Hoffmann-La Roche Ag Thiazolopyridine compounds, compositions and their use as tyk2 kinase inhibitors
US9834548B2 (en) * 2014-02-14 2017-12-05 Portola Pharmaceuticals, Inc. Pyridazine compounds as JAK inhibitors
JP6526065B2 (ja) 2014-02-28 2019-06-05 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
ES2749433T3 (es) * 2014-06-23 2020-03-20 Celgene Corp Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática
US10092541B2 (en) * 2014-08-15 2018-10-09 Celgene Corporation Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast
NO2721710T3 (es) 2014-08-21 2018-03-31
WO2016047678A1 (ja) 2014-09-25 2016-03-31 武田薬品工業株式会社 複素環化合物
EP3262049B1 (en) 2015-02-27 2022-07-20 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
EP3344624B8 (en) 2015-09-02 2023-11-29 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
CN109071546B (zh) 2016-02-24 2021-03-02 辉瑞大药厂 作为jak抑制剂的吡唑并[1,5-a]吡嗪-4-基衍生物
WO2018067432A1 (en) 2016-10-07 2018-04-12 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
US10323036B2 (en) 2016-10-14 2019-06-18 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
EP3528816A4 (en) 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
CN110114357B (zh) 2016-10-28 2022-05-31 百时美施贵宝公司 可用作IL-12、IL-23和/或IFNα反应的调节剂的杂双环化合物
EP3541817B1 (en) 2016-11-17 2020-12-23 Bristol-Myers Squibb Company Imidazopyridazine modulators of il-12, il-23 and/or ifn-alpha
GB2562702B (en) 2017-03-06 2022-05-18 Linear Shaped Ltd Frame and linear shaped charge
US10336752B2 (en) * 2017-03-08 2019-07-02 Nimbus Lakshmi, Inc. TYK2 inhibitors, uses, and methods for production thereof
MX2021013317A (es) 2019-04-30 2022-01-18 Celgene Corp Terapias de combinacion que comprenden inhibidores de apremilast y tyk2.

Also Published As

Publication number Publication date
KR20220002488A (ko) 2022-01-06
EP3962476A1 (en) 2022-03-09
JP2022537878A (ja) 2022-08-31
AU2020266143A1 (en) 2021-12-02
MX2021013317A (es) 2022-01-18
CL2021002847A1 (es) 2022-07-22
CA3138686A1 (en) 2020-11-05
WO2020223431A1 (en) 2020-11-05
EP3962475A1 (en) 2022-03-09
KR20220002489A (ko) 2022-01-06
BR112021021826A8 (pt) 2022-06-21
SG11202112018YA (en) 2021-11-29
CN114206333A (zh) 2022-03-18
IL287670A (en) 2021-12-01
MX2021013318A (es) 2022-01-31
CO2021015614A2 (es) 2021-12-10
BR112021021826A2 (pt) 2022-01-04
CO2021015622A2 (es) 2022-02-28
IL287665A (en) 2022-07-01
AU2019443366A1 (en) 2021-12-02
WO2020222773A1 (en) 2020-11-05
CN114269336A (zh) 2022-04-01
JP2022537877A (ja) 2022-08-31
BR112021021809A2 (pt) 2022-01-04
SG11202112043PA (en) 2021-11-29
CA3138473A1 (en) 2020-11-05
JP7453251B2 (ja) 2024-03-19

Similar Documents

Publication Publication Date Title
MA55799A (fr) Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2
IL282487A (en) TYK2 inhibitors and their use
MA44890A (fr) Compositions comprenant des souches bactériennes
GB201909190D0 (en) Therapeutic agents
MX2019008197A (es) Inhibidores de tgfb1 permisivos del contexto, espicificos de isoformas y uso de los mismos.
GB201909194D0 (en) Therapeutic agents
GB201909191D0 (en) Therapeutic agents
MA46716A (fr) Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie
IL286248A (en) tyk2 inhibitors and their use
IL284799A (en) TYK2 inhibitors and uses thereof
PH12021551282A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
IL279810A (en) Heteroaryl-converted sulfonamide compounds and their use as medicinal agents
IL276609A (en) Combined treatment with epilimod and glutamatergic factors
MA47074A (fr) Formes pharmaceutiques comprenant des inhibiteurs de canaux de task-1 et task-3 et leur utilisation pour le traitement des troubles respiratoires
MA52165A (fr) Inhibiteurs sélectifs de l'isoforme tgfbeta1 et utilisation associée
GB201902277D0 (en) Therapeutic agents
ZA202100092B (en) Modified cas9 protein and use thereof
IL278949A (en) Benzene sulfonamide compounds and their use as medicinal agents
GB201906804D0 (en) Therapeutic agents
MA55781A (fr) Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2
IL289531A (en) cd38 binding agents and uses thereof
IL288828A (en) Binding factors - cd38 and their use
PL3937949T3 (pl) Fitoekdyzony i ich pochodne do ich zastosowania w leczeniu upośledzenia funkcji oddechowych
MA53009A (fr) Agents inhibiteurs d'ask1
IT201800001753U1 (it) “corpo di bombetta da esercitazioni in acciaio ”